title: Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study.
abstract: This study compared immunogenicity and safety of DTaP(5)-IPV-Hib to DTaP(3)-IPV/Hib coadministered with PCV7 at 2, 3, and 4 months (primary series) and a fourth-dose booster at 12-18 months of age. Seroprotection rates for DTaP(5)-IPV-Hib were high (noninferior to DTaP(3)-IPV/Hib for the primary series) for antigens common to both vaccines and PCV7 antigens. Geometric mean concentration (GMC) for Hib antibodies were higher in the DTaP(5)-IPV-Hib group than the DTaP(3)-IPV/Hib group after the primary series and booster dose; GMCs or titers for other antigens were generally similar between groups after the primary series and booster dose. Safety profiles were similar between groups.
authors.affiliation: Hôpital Armand Trousseau and Université Pierre et Marie Curie Paris VI, Paris, France. emmanuel.grimprel@trs.aphp.fr
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Grimprel
authors.forename: Jacek
authors.initials: J
authors.lastname: Wysocki
authors.forename: Florence
authors.initials: F
authors.lastname: Boisnard
authors.forename: Stéphane
authors.initials: S
authors.lastname: Thomas
authors.forename: Grace
authors.initials: G
authors.lastname: Mwawasi
authors.forename: Donna
authors.initials: D
authors.lastname: Reynolds
mesh_terms: D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D023321:Poliovirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D016037:Single-Blind Method; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D023321:Poliovirus Vaccines; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate